Veru Inc (VERU) Stock Price, Quote & News

Latest News on VERU

May 28, 2025, 12:11 PM EDT - 2 days ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 6:30 AM EDT - 2 days ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 26, 2025, 9:36 PM EDT - 3 days ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 8, 2025, 12:42 PM EDT - 22 days ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 9:30 AM EDT - 22 days ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 22 days ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 6:30 AM EDT - 22 days ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 4 weeks ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 6 weeks ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 2 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 13, 2025, 2:35 PM EST - 3 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 6:30 AM EST - 3 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Jan 27, 2025, 10:34 AM EST - 4 months ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 6:30 AM EST - 4 months ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Dec 31, 2024, 8:30 AM EST - 5 months ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Nov 26, 2024, 8:30 AM EST - 6 months ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 7 months ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 7 months ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 8 months ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 11, 2024, 8:30 AM EDT - 9 months ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 10, 2024, 8:39 AM EDT - 10 months ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 10 months ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 10 months ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 10 months ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 11 months ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

Mar 22, 2024, 4:05 PM EDT - 1 year ago

Veru Reschedules Annual Meeting of Shareholders

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Feb 27, 2024, 7:15 PM EST - 1 year ago

Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Feb 20, 2024, 8:30 AM EST - 1 year ago

Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

Feb 8, 2024, 1:36 PM EST - 1 year ago

Veru Inc. (VERU) Q1 2024 Earnings Call Transcript

Feb 8, 2024, 6:30 AM EST - 1 year ago

Veru Reports Fiscal 2024 First Quarter Financial Highlights

Feb 6, 2024, 8:30 AM EST - 1 year ago

Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

Jan 31, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Jan 25, 2024, 8:30 AM EST - 1 year ago

Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

Jan 8, 2024, 8:30 AM EST - 1 year ago

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

Dec 19, 2023, 8:30 AM EST - 1 year ago

Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

Dec 14, 2023, 9:00 AM EST - 1 year ago

Market Cap	77.48M
Revenue (ttm)	16.89M
Net Income (ttm)	-37.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-223.80%
Debt to Equity Ratio	0.00

Volume	2,490,196
Avg Vol	2,258,064
Day's Range	N/A - N/A
Shares Out	146.58M
Stochastic %K	26%
Beta	-0.74
Analysts	Strong Sell
Price Target	$2.80